Literature DB >> 19956069

The prognostic value of p73 overexpression in colorectal carcinoma: a clinicopathologic, immunohistochemical, and statistical study of 204 patients.

Amira Arfaoui Toumi1, Olfa El Amine El Hadj, Lilia Kriaa Ben Mahmoud, Abd El Majid Ben Hmida, Ines Chaar, Lasaad Gharbi, Sabeh Mzabi, Saadia Bouraoui.   

Abstract

INTRODUCTION: The protein p73 is the first identified homolog of the tumor suppressor gene p53, but its function in tumor development has not been established. Indeed, the results regarding the p73 implication in colorectal cancers is still controversial. AIM: We investigated whether the p73 is implicated in colorectal cancer, whether the p73 expression is related to prognosis and whether the p73 expression is correlated with p21-ras or p53.
MATERIALS AND METHODS: We performed a comparative immunohistochemical analysis of p73, p53, and p21ras proteins in primary colorectal tumor with matched normal mucosa and metastasis from 204 patients with colorectal cancer. We correlated these expressions with clinicopathologic variables and we compared the different profiles between nonmucinous carcinoma and mucinous carcinoma.
RESULTS: In this study, we did not find any correlation between p73 expression, sex, age, site, differentiation and stage. Overexpression of p73 was significantly correlated with infiltrating growth pattern (P<0.0001) and nonmucinous carcinoma (P<0.0001). Furthermore, frequency and intensity of p73 expression were marquedly increased from normal mucosa (26%), to primary tumors (75%) and to metastasis (97%). Furthermore, expression of p73 was also correlated with shorter survival period. The prognostic significance of p73 expression remained, even after adjustment for the clinical and pathologic variables. The p73 expression was positively correlated only with p21ras expression (P<0.0001).
CONCLUSIONS: All these findings prove that p73 expression should be considered as a valuable poor prognostic marker. Our data also suggest that TP73 gene may play a role in colorectal carcinoma development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19956069     DOI: 10.1097/PAI.0b013e3181bcb2da

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  6 in total

Review 1.  Clinical implications of the deregulated TP73 isoforms expression in cancer.

Authors:  N Rodríguez; A Peláez; R Barderas; G Domínguez
Journal:  Clin Transl Oncol       Date:  2017-12-11       Impact factor: 3.405

2.  PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.

Authors:  Zheng Bo Hu; Xiao Hong Liao; Zun Ying Xu; Xiao Yang; Chao Dong; An Min Jin; Hai Lu
Journal:  Cancer Med       Date:  2015-12-02       Impact factor: 4.452

3.  Regulatory activity based risk model identifies survival of stage II and III colorectal carcinoma.

Authors:  Gang Liu; Chuanpeng Dong; Xing Wang; Guojun Hou; Yu Zheng; Huilin Xu; Xiaohui Zhan; Lei Liu
Journal:  Oncotarget       Date:  2017-09-28

4.  TP73 is a credible biomarker for predicting clinical progression and prognosis in cervical cancer patients.

Authors:  Hui Ye; Xia Guo
Journal:  Biosci Rep       Date:  2019-08-05       Impact factor: 3.840

5.  PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.

Authors:  Wenhu Li; Xianliao Zhang; Xinhua Xi; Yufa Li; Hong Quan; Shifeng Liu; Liqi Wu; Penghuan Wu; Wenxing Lan; Yongjun Shao; Haomiao Li; Kebing Chen; Zhengbo Hu
Journal:  Cancer Med       Date:  2020-04-29       Impact factor: 4.452

6.  ΔNp73, TAp73 and Δ133p53 Extracellular Vesicle Cargo as Early Diagnosis Markers in Colorectal Cancer.

Authors:  Javier Rodríguez-Cobos; David Viñal; Carmen Poves; María J Fernández-Aceñero; Héctor Peinado; Daniel Pastor-Morate; Mª Isabel Prieto; Rodrigo Barderas; Nuria Rodríguez-Salas; Gemma Domínguez
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.